Telo Genomics Statistics

Total Valuation

Telo Genomics has a market cap or net worth of CAD 5.02 million. The enterprise value is 5.13 million.

Market Cap	5.02M
Enterprise Value	5.13M

Important Dates

The last earnings date was Wednesday, February 25, 2026.

Earnings Date	Feb 25, 2026
Ex-Dividend Date	n/a

Share Statistics

Telo Genomics has 100.43 million shares outstanding. The number of shares has increased by 36.09% in one year.

Current Share Class	100.43M
Shares Outstanding	100.43M
Shares Change (YoY)	+36.09%
Shares Change (QoQ)	+0.04%
Owned by Insiders (%)	2.98%
Owned by Institutions (%)	0.10%
Float	97.44M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	-9.08
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.96
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.58

Financial Position

The company has a current ratio of 0.14

Current Ratio	0.14
Quick Ratio	0.08
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.08
Interest Coverage	-567.87

Financial Efficiency

Return on equity (ROE) is -438.32% and return on invested capital (ROIC) is -237.47%.

Return on Equity (ROE)	-438.32%
Return on Assets (ROA)	-119.76%
Return on Invested Capital (ROIC)	-237.47%
Return on Capital Employed (ROCE)	548.57%
Weighted Average Cost of Capital (WACC)	5.13%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -56.52% in the last 52 weeks. The beta is 0.18, so Telo Genomics's price volatility has been lower than the market average.

Beta (5Y)	0.18
52-Week Price Change	-56.52%
50-Day Moving Average	0.05
200-Day Moving Average	0.08
Relative Strength Index (RSI)	52.00
Average Volume (20 Days)	99,845

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-2.58M
Pretax Income	-2.62M
Net Income	-2.62M
EBITDA	-2.55M
EBIT	-2.58M
Earnings Per Share (EPS)	-0.03

Full Income Statement

Balance Sheet

The company has 50,110 in cash and 161,305 in debt, giving a net cash position of -111,195 or -0.00 per share.

Cash & Cash Equivalents	50,110
Total Debt	161,305
Net Cash	-111,195
Net Cash Per Share	-0.00
Equity (Book Value)	-553,325
Book Value Per Share	-0.01
Working Capital	-691,210

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.97 million and capital expenditures -22,001, giving a free cash flow of -1.99 million.

Operating Cash Flow	-1.97M
Capital Expenditures	-22,001
Free Cash Flow	-1.99M
FCF Per Share	-0.02

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Telo Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-36.09%
Shareholder Yield	-36.09%
Earnings Yield	-52.18%
FCF Yield	-39.66%

Stock Splits

The last stock split was on November 22, 2019. It was a reverse split with a ratio of 0.2.

Last Split Date	Nov 22, 2019
Split Type	Reverse
Split Ratio	0.2

Scores

Altman Z-Score	n/a
Piotroski F-Score	1